Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, announced it will host its 2026 capital markets day for investors and analysts on Tuesday, 8 September, at the London Stock Exchange. The event, which will be held in-person and via live webcast from 13:30 to 17:00 UK time, aims to outline the company's strategy for maximizing value in what it describes as the 'golden decade for biosimilars'. The formal part of the event will be webcast live, with in-person attendance by invitation only on a first-come, first-served basis. Details on how to access the live webcast are available here.
The capital markets day comes as Sandoz marks 20 years of pioneering biosimilars in 2026, a milestone that underscores the company's long-standing commitment to affordable biologic medicines. Biosimilars are lower-cost versions of biologic drugs that have lost patent protection, and Sandoz has been a key player in expanding patient access to these therapies. The company's focus on biosimilars is part of a broader growth strategy driven by its purpose: pioneering access for patients. With a portfolio of approximately 1,300 medicines addressing diseases from the common cold to cancer, Sandoz generated net sales of USD 11.1 billion in 2025.
In addition to the capital markets day, Sandoz plans to host an investor and analyst site visit in Slovenia from 9-10 November. This visit will provide further insight into the company's new biosimilars development and supply-chain hub. Attendance is again by invitation only on a first-come, first-served basis, and the event will not be webcasted. The Slovenia hub represents a significant investment in Sandoz's biosimilars infrastructure, positioning the company to capitalize on growing demand for affordable biologic therapies worldwide.
The announcements come amid a period of strong growth for the biosimilars market, driven by patent expiries of major biologic drugs and increasing healthcare cost pressures. Sandoz's leadership in this space, with over 20 years of experience, places it well to benefit from these trends. The capital markets day and site visit are expected to provide investors with a detailed look at the company's pipeline, manufacturing capabilities, and commercial strategy.
Forward-looking statements in the press release caution that actual outcomes may differ from expectations due to risks such as global economic conditions, exchange rates, legal provisions, market conditions, and competitor activities. Sandoz undertakes no obligation to publicly revise these statements except as required by law. The company, headquartered in Basel, Switzerland, traces its heritage back to 1886 and employs more than 20,000 colleagues of 100 nationalities, reaching over one billion patients globally.
